Discover Viatris

Mylan is now part of Viatris, a new global healthcare company committed to empowering people to live healthier at every stage of life.

Although this Mylan site remains active for now, we encourage you to visit the Viatris site to learn more about our commitment to increasing access to quality medicines for patients when and where they need them.

Dec 17, 2014

Mylan to Present at the J.P. Morgan 33rd Annual Healthcare Conference

PITTSBURGH, Dec. 17, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the Company will present at the J.P. Morgan 33rd Annual Healthcare Conference on Tuesday Jan. 13, 2015, in San Francisco.

The presentation is scheduled to begin at 7:30 p.m. ET on Tuesday Jan. 13, 2015.  Interested parties can access a live webcast of the presentation via the investor relations section of Mylan's Web site at www.mylan.com/investor. An archived version will also be available following the live presentation and can be accessed at the same location for a limited time.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. Learn more at mylan.com

SOURCE Mylan Inc.